InMed Pharmaceuticals (INM) Liabilities from Discontinued Operations (2025 - 2026)
InMed Pharmaceuticals' (INM) quarterly Liabilities from Discontinued Operations came in at 810334.0 in Q1 2026, up 367.22% quarter-over-quarter from 173438.0 in Q2 2025.
InMed Pharmaceuticals (INM) Liabilities from Discontinued Operations (2025 - 2026) Analysis & Trends
InMed Pharmaceuticals' Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 810334.0 for Q1 2026.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 810334.0 in Q1 2026; TTM through Mar 2026 was 810334.0, a N/A change from a year earlier, with the FY2025 full-year figure at 173438.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations advanced to 810334.0 in Q1 2026 per INM's latest filing, from 173438.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 810334.0 in Q1 2026 and bottomed at 173438.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 810,334.00 |
| Mar 31, 2026 | 810,334.00 |
| Jun 30, 2025 | 173,438.00 |
| Jun 30, 2025 | 173,438.00 |